Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer
The global antidepressant drugs market is expected to experience a substantial CAGR from 2024 to 2030. This growth is driven by rising depression cases worldwide, alongside a greater understanding of depression. Additionally, the market for antidepressants is projected to expand due to numerous ongoing research initiatives, collaborations among healthcare providers, researchers, and industry stakeholders, as well as strategic partnerships. These factors are poised to contribute to the overall expansion of the antidepressant drugs market throughout the forecast period spanning 2024 to 2030.
/EIN News/ -- New York, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer
The global antidepressant drugs market is expected to experience a substantial CAGR from 2024 to 2030. This growth is driven by rising depression cases worldwide, alongside a greater understanding of depression. Additionally, the market for antidepressants is projected to expand due to numerous ongoing research initiatives, collaborations among healthcare providers, researchers, and industry stakeholders, as well as strategic partnerships. These factors are poised to contribute to the overall expansion of the antidepressant drugs market throughout the forecast period spanning 2024 to 2030.
DelveInsight’s Anti-Depressant Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-depressant drugs companies’ market shares, challenges, anti-depressant drugs market drivers, barriers, trends, and key market anti-depressant drugs companies in the market.
Key Takeaways from the Anti-Depressant Drugs Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global anti-depressant drugs market during the forecast period.
- Notable anti-depressant drugs companies such as AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Organon group of companies, Takeda Pharmaceutical Company Limited, Novartis AG, Biogen Inc., Sage Therapeutics, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, Inc., Lupin, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr Reddy’s Laboratories Ltd., and several others, are currently operating in the anti-depressant drugs market.
- In September 2023, the FDA approved a new drug Exxua by Fabre-Kramer Pharmaceuticals to treat major depressive disorder in adults.
- In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD).
- In August 2022, the FDA approved Auvelity which is an extended-release dextromethorphan/bupropion tablet intended for the treatment of major depressive disorder in adults.
To read more about the latest highlights related to the anti-depressant drugs market, get a snapshot of the key highlights entailed in the Global Anti-Depressant Drugs Market Report
Anti-Depressant Drugs Overview
Anti-depressant drugs, a cornerstone of mental health treatment, work to alleviate symptoms of depression by regulating neurotransmitters in the brain. These medications, which include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and others, aim to restore the balance of chemicals that affect mood and emotions. For many individuals, these drugs offer a path to managing the debilitating effects of depression, helping to improve quality of life and restore a sense of normalcy.
However, the effectiveness of anti-depressants can vary widely from person to person, and finding the right medication often involves a process of trial and error. Alongside their benefits, these drugs may come with side effects ranging from mild to severe, underscoring the importance of careful monitoring by healthcare professionals. Despite these challenges, anti-depressants remain a vital tool in the treatment of depression, offering hope and relief to millions of people worldwide who grapple with this complex and often misunderstood mental health condition.
Anti-Depressant Drugs Market Insights
In 2023, North America led the anti-depressant drugs market, supported by key factors such as the increasing prevalence of neurological and psychiatric disorders, a strong healthcare infrastructure, the presence of major industry players, rising product development endeavors, and other significant factors. The region is expected to experience substantial growth in the anti-depressant drugs market from 2024 to 2030.
According to the National Institute of Mental Health (NIMH) in 2022, approximately 52.9 million individuals, representing 21% of the population, experienced mental illness in the United States in 2020. Additionally, 14.2 million people in the United States had serious mental illness in 2020, as reported by the same source. The NIMH also noted that around 21.0 million adults in the United States had at least one major depressive episode in 2020.
The surge in product development activities in the region is another factor contributing to the growth of the anti-depressant drugs market. For instance, in September 2023, Fabre-Kramer Pharmaceuticals received approval from the FDA for Exxua, a new drug designed to treat major depressive disorder in adults. Notably, this drug boasts fewer common side effects compared to other medications for depression.
In summary, these factors are expected to drive the expansion of the anti-depressant drugs market in North America throughout the forecast period from 2024 to 2030.
To know more about why North America is leading the market growth in the anti-depressant drugs market, get a snapshot of the Anti-Depressant Drugs Market Outlook
Anti-Depressant Drugs Market Dynamics
The increasing prevalence of mental health conditions like depression and obsessive-compulsive disorder is fueling the expansion of the anti-depressant drugs market. According to the World Health Organization's 2022 data, an estimated 970 million people, or about 1 in 8 individuals globally, were living with a mental disorder in 2019. The report highlighted anxiety and depressive disorders as the most prevalent mental health conditions, affecting 301 million people, including 58 million children and adolescents, in 2019 worldwide.
In 2019, approximately 280 million people, constituting 3.8% of the global population, including 23 million children and adolescents, were reported to have depression. The continuous research efforts aimed at developing new anti-depressant medications are expected to drive market growth in the foreseeable future. For instance, Autobahn Therapeutics initiated a Phase I clinical trial of ABX-002 in November 2022 for the treatment of major depressive disorder.
However, challenges such as regulatory compliance, safety concerns associated with anti-depressant drugs, and the social stigma and discrimination faced by individuals with mental health conditions may hinder the overall growth of the anti-depressant drugs market.
Get a sneak peek at the anti-depressant drugs market dynamics @ Anti-Depressant Drugs Market Dynamics Analysis
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2021–2030 |
| Key Anti-Depressant Drugs Companies | AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Organon group of companies, Takeda Pharmaceutical Company Limited, Novartis AG, Biogen Inc., Sage Therapeutics, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, Inc., Lupin, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr Reddy’s Laboratories Ltd., among others |
Anti-Depressant Drugs Market Assessment
-
Anti-Depressant Drugs Market Segmentation
- Anti-Depressant Drugs Market Segmentation By Drug Type: Selective Serotonin Reuptake Inhibitors (SSRI), Selective-norepinephrine Reuptake Inhibitors (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitors (MAOI), and Others
- Anti-Depressant Drugs Market Segmentation By Application: Major Depressive Disorder (MDD), Obsessive-compulsive Disorder (OCD), General Anxiety Disorder (GAD), Panic Disorder (PD), and Others
- Anti-Depressant Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the anti-depressant drugs market are set to emerge as the trendsetter explore @ Anti-Depressant Drugs Companies
Table of Contents
| 1 | Report Introduction |
| 2 | Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Key Factors Analysis |
| 5 | Porter’s Five Forces Analysis |
| 6 | Anti-Depressant Drugs Market Layout |
| 7 | Global Company Share Analysis – Key 3-5 Companies |
| 8 | Anti-Depressant Drugs Market Company and Product Profiles |
| 9 | Project Approach |
| 10 | About DelveInsight |
Interested in knowing the anti-depressant drugs market by 2030? Click to get a snapshot of the Anti-Depressant Drugs Market Trends
Related Reports
Major Depressive Disorder Epidemiology Forecast
Major Depressive Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted major depressive disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Major Depressive Disorder Pipeline
Major Depressive Disorder Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key major depressive disorder companies, including GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, among others.
Treatment-Resistant Depression Pipeline
Treatment-Resistant Depression Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key treatment-resistant depression companies, including Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, among others.
Bipolar Depression Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including Vanda Pharmaceuticals, Reviva Pharmaceuticals, SK BIOPHARMACEUTICALS, Pear Therapeutics, Arvelle Therapeutics, Janssen Research & Development, Sunovion Pharmaceuticals, Lyndra Therapeutics, ILTOO Pharma, COMPASS Pathways, NRx Pharmaceuticals, Carlsson Research AB, Sunovion, SAGE Therapeutics, Alzamend Neuro, OWP Pharmaceuticals, Entheogenix Biosciences, among others.
Postpartum Depression Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key postpartum depression companies, including Sage Therapeutics, Epharmix, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
